Regeneron Pharmaceuticals Inc (REGN) Receives $469.27 Consensus Target Price from Brokerages
Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have received a consensus rating of “Hold” from the thirty brokerages that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, fifteen have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $469.27.
A number of analysts recently commented on the company. BTIG Research reiterated a “buy” rating and set a $520.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, November 22nd. BMO Capital Markets set a $444.00 price target on Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Monday, November 27th. Citigroup lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $480.00 to $380.00 in a report on Friday, December 1st. Piper Jaffray Companies reissued a “buy” rating and set a $540.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, November 13th. Finally, JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, November 28th.
Regeneron Pharmaceuticals (NASDAQ REGN) traded up $0.25 during mid-day trading on Friday, hitting $371.53. The stock had a trading volume of 665,000 shares, compared to its average volume of 772,900. Regeneron Pharmaceuticals has a 52-week low of $340.09 and a 52-week high of $543.55. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $40,310.00, a PE ratio of 33.74, a P/E/G ratio of 1.43 and a beta of 1.52.
Large investors have recently bought and sold shares of the stock. Fieldpoint Private Securities LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $130,000. Steward Partners Investment Advisory LLC lifted its position in shares of Regeneron Pharmaceuticals by 495.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 307 shares in the last quarter. Virtu KCG Holdings LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $206,000. Vident Investment Advisory LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth about $200,000. Finally, People s United Financial Inc. lifted its position in shares of Regeneron Pharmaceuticals by 656.7% in the second quarter. People s United Financial Inc. now owns 454 shares of the biopharmaceutical company’s stock worth $223,000 after buying an additional 394 shares in the last quarter. Institutional investors own 66.82% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.